NCT01895127终止2 期
Efficacy and Safety of Eculizumab for Treatment of Antibody-mediated Rejection Following Renal Transplantation.
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 11
- 试验地点
- 3
- 主要终点
- Percent Change in Estimated Glomerular Filtration (eGFR) Rate
研究概览
简要总结
This is an open-label analysis that will compare eculizumab versus Plasmapheresis (PP) and Immunoglobulin (IVIg) for the treatment of antibody-mediated rejection (AMR) in renal transplant recipients. All patients will be evaluated from the time of AMR diagnosis for 12 months.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adult renal transplant recipients, men and women between 18 and 75 years of age.
- •Any patient with acute graft dysfunction (elevation of creatinine above post transplant nadir)
- •AND, two out of three, of the following Inclusion Criteria:
- •Presence of circulating anti human leukocyte antigen (HLA) antibody (DSA "donor specific antibody").
- •Histological findings compatible with Banff Class II or III AMR on transplant biopsy.
- •Peritubular capillary c4d positivity on transplant biopsy.
排除标准
- •Patients that have received eculizumab prior to enrolling in the study.
- •Patients with ongoing non-acute antibody mediated rejection.
- •Patients with predominantly chronic antibody mediated rejection or interstitial fibrosis/tubular atrophy.
- •History of severe cardiac disease (e.g., New York Heart Association [NYHA] Functional Class III or IV, myocardial infarction ≤ 6 months of randomization, ventricular tachyarrhythmias requiring ongoing treatment, unstable angina or other significant cardiovascular diseases)
- •Prior splenectomy
- •Has a known bleeding disorder
- •Has any active bacterial or other infection which is clinically significant in the opinion of the Investigator and is a contraindication to transplantation
- •Has participated in any other investigational drug study or was exposed to an investigational drug or device within 30 days of screening
- •Has received rituximab (Rituxan®) ≤ 3 months prior to screening
- •Has received bortezomib (Velcade®) ≤ 3 months prior to screening
- •Has received alemtuzumab (Campath®) ≤ 6 months prior to screening
- •Need for concurrent treatment with anti thymocyte globulin (Thymoglobulin®)
- •Hypersensitivity to murine proteins or to one of the product excipients
- •History of illicit drug use or alcohol abuse within the previous year
- •Unresolved meningococcal disease
- •Pregnancy or lactation
- •Current cancer or a history of cancer within the 5 years prior to screening with the exception of patients who have successfully treated non-metastatic basal or squamous cell carcinoma of the skin; carcinoma in situ of the cervix; or breast carcinoma in situ
- •Any medical condition that, in the opinion of the Investigator, might interfere with the patient's participation in the study, poses an added risk for the patient, or confounds the assessment of the patient Active infection with Hepatitis B (HBV), Hepatitis C (HCV) or human immunodeficiency virus (HIV)
研究组 & 干预措施
Standard of Care
Active Comparator
- Plasmapheresis (PP) x 3, at 40-60 cc/kg.
- Immunoglobulin (IVIg), to be administered after each PP
干预措施: Immunoglobulin (Biological)
Standard of Care
Active Comparator
- Plasmapheresis (PP) x 3, at 40-60 cc/kg.
- Immunoglobulin (IVIg), to be administered after each PP
干预措施: Plasmapheresis (Procedure)
Soliris (eculizumab)
Experimental
- 1200 mg first dose (Time: Screening/Week "0", after Biopsy Proven AMR)
- 900 mg weekly for 4 doses (Weeks 1, 2, 3, 4)
- 1200 mg week 5
- Week 6: If donor specific antibody < 50% of baseline DSA then no further treatment, otherwise 1200 mg weeks 7, 9
干预措施: Eculizumab (Drug)
结局指标
主要结局
Percent Change in Estimated Glomerular Filtration (eGFR) Rate
时间窗: Month 3
Percent change in eGFR rate at 3 months post-treatment using the modified Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation.
次要结局
未报告次要终点
研究者
Anil K. Chandraker, MD
Medical Director of Kidney and Pancreas Transplantation
Brigham and Women's Hospital
研究点 (3)
Loading locations...
相似试验
已完成
2 期
Open Label Controlled Trial of Eculizumab in Adolescent Patients With Plasma Therapy-Resistant aHUSAtypical Hemolytic Uremic SyndromeNCT00844844Alexion Pharmaceuticals, Inc.1
已完成
2 期
Open Label Controlled Trial of Eculizumab in Adolescent Patients With Plasma Therapy-Sensitive aHUSAtypical Hemolytic Uremic SyndromeNCT00844428Alexion Pharmaceuticals, Inc.5
已完成
2 期
Open Label Controlled Trial of Eculizumab in Adult Patients With Plasma Therapy-Resistant aHUSAtypical Hemolytic Uremic SyndromeNCT00844545Alexion Pharmaceuticals, Inc.16
已完成
2 期
Open Label Controlled Trial of Eculizumab in Adult Patients With Plasma Therapy-sensitive Atypical Hemolytic Uremic Syndrome (aHUS)Atypical Hemolytic Uremic SyndromeNCT00838513Alexion Pharmaceuticals, Inc.15
已完成
4 期
Eculizumab Pharmacokinetics/Pharmacodynamics Study in Pediatric/Adolescent Paroxysmal Nocturnal Hemoglobinuria (PNH)Hemoglobinuria, ParoxysmalNCT00867932Alexion Pharmaceuticals, Inc.7